On February 26, 2021 Scorpion Therapeutics reported that Dr. Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis (Press release, Scorpion Therapeutics, FEB 26, 2021, View Source;utm_medium=rss&utm_campaign=scorpion-therapeutics-announces-leadership-change [SID1234575678]). The Board of Directors is currently evaluating candidates to lead the Company’s next phase of growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am humbled by the trust the Board has placed in me and honored to have an opportunity to lead this organization until a permanent CEO is identified," said Dr. Friedman. "Scorpion Therapeutics has strong momentum with its lead precision oncology programs, multiple discovery platforms, and proven leadership from its veteran R&D team."

Dr. Friedman was previously a Founder and Director at Raze Therapeutics and, together with Scorpion’s co-founder Keith Flaherty, founder of the oncology platform discovery company Vivid Biosciences, where he served as President and Chief Executive Officer.

Scorpion Therapeutics has secured $270 million in financing since it was founded in the first quarter of 2020, and will continue development of Scorpion’s drug hunting engine, which integrates state-of-the-art capabilities across multiple fields of translational medicine, chemical biology, medicinal chemistry, and data science, as well as the advancement of Scorpion’s growing portfolio, which includes several therapeutic candidates across a range of biological approaches for tumor targeting.